Document is current
Any future updates will be listed below
-
Authors
Xiong, Ying https://orcid.org/0000-0001-7644-014X
Krebs, Kristi https://orcid.org/0000-0003-0494-2751
Jermy, Bradley
Karlsson, Robert https://orcid.org/0000-0002-8949-2587
Pasman, Joëlle A.
Nguyen, Thuy-Dung
Gong, Tong
Kowalec, Kaarina
Rück, Christian https://orcid.org/0000-0002-8742-0168
Sigström, Robert https://orcid.org/0000-0003-1505-1532
Jonsson, Lina https://orcid.org/0000-0002-3175-103X
Clements, Caitlin C.
Hörbeck, Elin
Andersson, Evelyn
Bäckman, Julia
,
,
Ganna, Andrea https://orcid.org/0000-0002-8147-240X
German, Jakob https://orcid.org/0009-0002-1257-7782
Sullivan, Patrick F. https://orcid.org/0000-0002-6619-873X
Landén, Mikael
Lehto, Kelli
-
Funding
Funding for this research was provided by:
Forskningsrådet om Hälsa, Arbetsliv och Välfärd (2021-00132)
- License Information
-
More Information
Article History
Received: 7 August 2024
Revised: 13 May 2025
Accepted: 11 June 2025
First Online: 26 June 2025
Competing interests
: PFS is a paid advisor and shareholder for Neumora Therapeutics. ML has received lecture honoraria from Lundbeck pharmaceuticals outside the submitted work. All other authors report no biomedical financial interests or potential conflicts of interest related to this work.
